Parametric Portfolio Associates’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-77,021
Closed -$2.9M 3639
2021
Q1
$2.9M Sell
77,021
-242,678
-76% -$6.05M ﹤0.01% 2542
2020
Q4
$5.44M Buy
319,699
+50,462
+19% +$632K ﹤0.01% 2024
2020
Q3
$1.26M Sell
269,237
-19,792
-7% -$101K ﹤0.01% 2773
2020
Q2
$1.76M Buy
289,029
+228,718
+379% +$942K ﹤0.01% 2576
2020
Q1
$137K Buy
60,311
+37,768
+168% +$160K ﹤0.01% 3658
2019
Q4
$103K Sell
22,543
-33,771
-60% -$134K ﹤0.01% 3858
2019
Q3
$218K Buy
56,314
+11,459
+26% +$62.9K ﹤0.01% 3677
2019
Q2
$270K Buy
44,855
+31,173
+228% +$298K ﹤0.01% 3624
2019
Q1
$183K Sell
13,682
-1,559
-10% -$17.8K ﹤0.01% 3733
2018
Q4
$142K Sell
15,241
-12,864
-46% -$153K ﹤0.01% 3730
2018
Q3
$391K Sell
28,105
-13,962
-33% -$208K ﹤0.01% 3532
2018
Q2
$665K Buy
42,067
+6,517
+18% +$114K ﹤0.01% 3229
2018
Q1
$611K Buy
35,550
+13,716
+63% +$268K ﹤0.01% 3249
2017
Q4
$479K Sell
21,834
-5,055
-19% -$163K ﹤0.01% 3346
2017
Q3
$1.1M Buy
26,889
+3,330
+14% +$105K ﹤0.01% 2986
2017
Q2
$709K Buy
23,559
+13,642
+138% +$426K ﹤0.01% 3172
2017
Q1
$358K Sell
9,917
-37,739
-79% -$1.66M ﹤0.01% 3368
2016
Q4
$2.39M Sell
47,656
-2,211
-4% -$116K ﹤0.01% 2257
2016
Q3
$2.62M Buy
49,867
+6,102
+14% +$291K ﹤0.01% 2151
2016
Q2
$1.81M Buy
43,765
+1,101
+3% +$47.9K ﹤0.01% 2393
2016
Q1
$1.73M Buy
42,664
+37,021
+656% +$1.27M ﹤0.01% 2521
2015
Q4
$234K Buy
+5,643
New +$189K ﹤0.01% 3666

Parametric Portfolio Associates's FPRX Position: Q2 2021 in Review

Parametric Portfolio Associates sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 77,021 shares — an estimated $2.9M sold.

Parametric Portfolio Associates first reported a position in FPRX in Q4 2015 and held it in 22 quarters. The position peaked at $5.44M in Q4 2020. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.

  • Parametric Portfolio Associates reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
  • Parametric Portfolio Associates sold 77,021 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $2.9M.
  • Parametric Portfolio Associates first reported a position in Five Prime Therapeutics, Inc. in Q4 2015 and held it in 22 quarters.
  • Parametric Portfolio Associates's Five Prime Therapeutics, Inc. position peaked at $5.44M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.

Based on Parametric Portfolio Associates's 13F filing for Q2 2021, filed 13 Aug 2021.